Jaguar Health

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. The firm focuses on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. It operates through the Human Health and Animal Health segments. The Human Health segment manufactures human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment commercializes prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Jaguar Health reports revenue growth and eyes cancer therapy market

Jaguar Health's Q1 2024 performance showed revenue growth and improved financial metrics. The company's strategic focus on cancer supportive care and rare diseases positions it for future growth. Challenges include trial result uncertainties and regulatory timelines, but opportunities exist in market expansion and new programs.

Jaguar Health reports revenue growth and promising clinical trial results

Jaguar Health's Q2 2024 earnings call showcases revenue growth, positive clinical trial outcomes, and strategic plans for product launches and FDA discussions. The company's focus on improving patient outcomes and expanding its product reach positions it for future success in the healthcare market.

Jaguar Health reports revenue growth and advances in cancer care

Jaguar Health's Q3 performance reflects revenue growth, successful trial outcomes, and a focus on cancer patient care through innovative products.
While facing challenges in regulatory processes and financial metrics, the company is well-positioned to capitalize on opportunities in rare diseases and oncology.
Overall, Jaguar Health's strategic initiatives and commitment to addressing critical medical needs position it for potential growth and impact in the healthcare sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. It operates through the Human Health and Animal Health segments. The Human Health segment is involved in manufacturing human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment includes commercializing prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

SAN FRANCISCO, CA / ACCESSWIRE / August 3, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, is presenting at an invitation-only lunch gathering of the Wall Street Wonders Investment Group in New York City at 1:30 p.m. EDT on Friday August 4, 2023.

Jaguar Health to Present Aug 4th at Wall Street Wonders Investment Group Luncheon in NYC

Napo Pharmaceuticals, a Jaguar Health company and the manufacturer of crofelemer, is supporting this physician-generated IND SAN FRANCISCO, CA / ACCESSWIRE / August 1, 2023 / Jaguar Health (NASDAQ:JAGX) ("the Company") today announced the activation by the U.S. Food and Drug Administration (FDA) of a physician-requested Investigational New Drug (IND) application to evaluate crofelemer for treatment of uncontrolled diarrhea in a patient with short bowel syndrome (SBS), a rare and complex condition characterized by diarrhea and/or severe malabsorption of fluids and nutrients. Napo Pharmaceuticals, a Jaguar company, is supporting this investigator-initiated trial of crofelemer, the Company's oral anti-diarrheal prescription drug.

Jaguar Health Announces FDA Activation of Third-Party Investigational New Drug (IND) Application for Evaluation of Crofelemer for Treatment of Uncontrolled Diarrhea in Patient with Short Bowel Syndrome (SBS)

Canalevia®-CA1 is currently FDA conditionally approved for treatment of CID in dogs and is the first and only treatment for CID in dogs to receive any type of approval from FDA Crofelemer, Jaguar's novel, oral plant-based product sustainably harvested from the Croton lechleri tree, is the active ingredient in Canalevia-CA1 SAN FRANCISCO, CA / ACCESSWIRE / July 26, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX), under its Jaguar Animal Health tradename for the veterinary market, today announced that two leading veterinary oncologists, Laura D. Garrett, DVM, Diplomate ACVIM (Oncology) and Angharad Waite, VMD, DACVIM (Oncology), will serve as Principal Investigators for the company's planned clinical field study of Canalevia®-CA1 (crofelemer delayed-release tablets), the company's U.S. Food and Drug Administration (FDA) conditionally approved prescription drug for the treatment of chemotherapy-induced diarrhea (CID) in dogs, to support full approval of the product.

Jaguar Health Names Principal Investigators for Clinical Trial to Support Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

SAN FRANCISCO, CA / ACCESSWIRE / July 7, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the voting results of the Company's 2023 Annual Meeting of Stockholders held on July 7, 2023. Five proposals were submitted to and approved by the stockholders of the Company at the Annual Meeting.

Jaguar Health Reports Approval of All Proposals at 2023 Annual Meeting of Stockholders

MVID is a life-threatening and ultra-rare autosomal recessive disease that affects newborns and children, leading to intestinal failure, significant morbidity and even death from severe secretory diarrhea SAN FRANCISCO, CA / ACCESSWIRE / June 28, 2023 / Napo Pharmaceuticals Inc., a Jaguar Health, Inc. (NASDAQ:JAGX) company, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a new crofelemer powder for oral solution formulation for the treatment of microvillus inclusion disease (MVID). "I am very happy that we have submitted the IND for crofelemer powder for oral solution for the treatment of MVID, an ultra-rare congenital diarrheal disorder (CDD)," said Lisa Conte, Jaguar's President and CEO.

Napo Pharmaceuticals, a Jaguar Health Company, Submits Investigational New Drug (IND) Application to FDA for Microvillus Inclusion Disease

SAN FRANCISCO, CA / ACCESSWIRE / June 26, 2023 / Jaguar Health, Inc. (Nasdaq:JAGX) announced today that the Take C.H.A.R.G.E. (Canine Health And ReGistry Exchange) has joined the Global Initiative for Veterinary Cancer Surveillance - an international network of veterinary cancer registries with a mission to: 1) promote international collaborations in animal cancer surveillance and research; 2) create a consensus on and foster the establishment of standardized methods for animal cancer coding and reporting; 3) provide an inclusive channel to exchange information between veterinary cancer registries.

First U.S.-Based Canine Cancer Registry, Founded by Jaguar Health, Joins International Network to Help Advance Canine and Human Cancer Research

Diarrhea is a highly neglected and unmet burden of cancer treatment in both people and dogs; A Jaguar-sponsored Gallup survey found that the incidence of U.S. dogs diagnosed with cancer in 2021 was approximately five times the incidence of cancer diagnosed in people SAN FRANCISCO, CA / ACCESSWIRE / June 22, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that the Company is launching an AI-driven series of disease awareness educational content on social media regarding cancer therapy-related diarrhea in dogs and people. The series will also include content about HIV-related diarrhea in humans.

Jaguar Health Launching AI-Driven Social Media Disease Awareness Education Series Regarding Cancer Therapy-Related Diarrhea in Dogs and People

Reminder: Jaguar to Present at MedInvest Oncology Investor Conference Wednesday, June 21, 2023 at 6:00 p.m. EDT. Click Here to Register for Event Reminder: Ladenburg Thalmann to Host Virtual Discussion June 22, 2023 at 1:00 PM EDT with Jaguar CEO and Leading Patient Advocates on Impact of Cancer Therapy-related Diarrhea on Patients & Importance of the Patient Voice in Supportive Care; Click Here to Register for Event SAN FRANCISCO, CA / ACCESSWIRE / June 20, 2023 / Jaguar Health, Inc. (Nasdaq:JAGX) today announced that Napo Pharmaceuticals, Jaguar's wholly owned subsidiary, is now a Corporate Partner of the Multinational Association of Supportive Care in Cancer (MASCC).

Jaguar Health Subsidiary Becomes Corporate Partner of Multinational Association of Supportive Care in Cancer (MASCC)

Reminder: Ladenburg Thalmann to host virtual discussion June 22, 2023 at 1:00 PM EDT with Jaguar CEO and leading patient advocates on impact of cancer therapy-related diarrhea on patients & importance of the patient voice in supportive care; Click here to register for event Jaguar recently completed patient enrollment in its ongoing pivotal, Phase 3 OnTarget clinical trial of crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy with or without chemotherapy SAN FRANCISCO, CA / ACCESSWIRE / June 15, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that at 6 p.m. EDT on Wednesday, June 21, 2023, Lisa Conte, Jaguar's president, founder, and CEO, will present virtually at the MedInvest Oncology Investor Conference and will be available to participate in virtual one-on-one meetings during the event.

Jaguar Health to Present June 21st at MedInvest Oncology Investor Conference

Click here to register for this virtual event taking place at 1:00 PM Eastern on June 22, 2023 Jaguar recently completed patient enrollment in its ongoing pivotal, Phase 3 OnTarget clinical trial of crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy with or without chemotherapy SAN FRANCISCO, CA / ACCESSWIRE / June 14, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Ladenburg Thalmann is hosting a live virtual "Duologue Series" discussion at 1:00 p.m. EDT on June 22, 2023 with Lisa Conte, Jaguar's founder, president and CEO.

Ladenburg Thalmann to Host Virtual Discussion June 22nd with Jaguar Health CEO and Leading Patient Advocates on Impact of Cancer Therapy-related Diarrhea on Patients & Importance of the Patient Voice in Supportive Care

After losing some value lately, a hammer chart pattern has been formed for Jaguar Animal Health, Inc. (JAGX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Jaguar Animal Health, Inc. (JAGX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

First U.S.-Based Canine Cancer Registry, Founded by Jaguar Health, to Join International Consortium of Canine Cancer Registries SAN FRANCISCO, CA / ACCESSWIRE / June 8, 2023 / Jaguar Health, Inc. (Nasdaq:JAGX) ("Jaguar") today announced that it and the cosponsors of the Take C.H.A.R.G.E Canine Cancer Registry (Canine Health And ReGistry Exchange), joined by their canine friends, leading veterinary oncologists, and child health advocates at a briefing on Capitol Hill for legislative staff, called for increased support to continue the expansion of Take C.H.A.R.G.E., the first and only U.S. canine cancer registry, and to drive awareness and increase funding for comparative oncology research, which focuses on naturally occurring cancer in dogs as models for both canine and human cancer research.

Canine and Child Cancer Research Advocates Call for Support as Capitol Hill "Goes to the Dogs"

Dr. Radaelli appointed Interim Executive Director of Napo Therapeutics S.p.A., the corporation established by Jaguar Health in Italy in 2021 that focuses on expanding crofelemer access in Europe SAN FRANCISCO, CA / ACCESSWIRE / June 7, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that on April 24, 2023, Massimo Radaelli, PhD, a European pharmaceutical industry leader and entrepreneur with more than 30 years of experience in the biopharmaceutical sector and innovation in therapies dedicated to rare diseases, was named Commander of the Italian Republic for Special Merits, the highest ranking honor of the Italian Republic bestowed upon a civilian by the President of the Republic of Italy and the Prime Minister of Italy, in recognition for "merit acquired in the fields of Science and the BioPharma Industry with a particular focus in Rare and Neglected diseases.

European Pharmaceutical Industry Leader and Entrepreneur Massimo Radaelli, PhD Named Commander of the Italian Republic for Special Merits

256-patient enrollment target met plus 11% over-enrollment; Primary endpoint based on patient reported outcomes from study expected in October 2023 SAN FRANCISCO, CA / ACCESSWIRE / May 25, 2023 / Jaguar Health, Inc. (Nasdaq:JAGX) ("Jaguar" or the "Company") today announced that the Company has successfully over-enrolled its global, pivotal, Phase 3 OnTarget clinical trial of crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy with or without chemotherapy. "As anticipated, we over-enrolled our ongoing placebo-controlled OnTarget trial by 11% after completion of the targeted enrollment of 256 patients," said Pravin Chaturvedi, PhD, Jaguar's Chair of the Scientific Advisory Board and Chief Scientific Officer, "and we look forward to the expected availability of top line results from this study in October 2023.

Jaguar Announces Over-Enrollment in its Pivotal Phase 3 OnTarget Trial of Crofelemer for Prophylaxis of Cancer Therapy-Related Diarrhea

SAN FRANCISCO, CA / ACCESSWIRE / May 24, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that Stacey Tinianov, MPH, a Board Certified Patient Advocate, has joined the Company's Scientific Advisory Board (SAB). "We are very pleased that Stacey has joined our SAB," said Pravin Chaturvedi, PhD, Jaguar's Chair of the Scientific Advisory Board and Chief Scientific Officer.

Board Certified Patient Advocate Stacey Tinianov, MPH, Joins Jaguar Health's Scientific Advisory Board

Announces Focus on Four Cancers Common to Children & Canines for Upcoming Capitol Hill Briefing, Commitment to Advancing Comparative Oncology According to the National Cancer Institute, Roughly 6 Million New Cancer Diagnoses are Made in Dogs Each Year in the U.S. SAN FRANCISCO, CA / ACCESSWIRE / May 23, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) announced the one-year anniversary of the Take C.H.A.R.G.E. (Canine Health And ReGistry Exchange) and an approximately 40 percent increase in canine cancer records on the second annual National Canine Cancer Awareness Day (May 23rd).

Take C.H.A.R.G.E. Registry Marks One-Year Anniversary on National Canine Cancer Awareness Day, With Database Grown 40%

SAN FRANCISCO, CA / ACCESSWIRE / May 19, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that the Company's New Employee Inducement Award Plan (the "Inducement Award Plan"), which was adopted by Jaguar's Board of Directors effective June 16, 2020, has been replenished with 499,171 shares of the Company's common stock, par value $0.0001 per share (the "Common Stock"). These 499,171 shares are in addition to (a) the 2,222 shares of Common Stock registered on the Company's Form S-8 filed on May 28, 2021 (File No.

Jaguar Health Announces Replenishment of New Employee Inducement Plan Under Nasdaq Listing Rule 5635(c)(4)

Jaguar Animal Health's Canalevia®-CA1 is the first and only treatment for chemotherapy-induced diarrhea (CID) in dogs to receive FDA conditional approval and is widely available through prominent pet retailers in the U.S. SAN FRANCISCO, CA / ACCESSWIRE / May 16, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that on Thursday, May 18, 2023 Lisa Conte, Jaguar's president, founder, and CEO, will present at the virtual Lytham Partners Spring 2023 Investor Conference and take part in an Animal Health Panel Discussion during the event. Company Webcast The Company's webcast presentation will be available for online viewing at 9:00 a.m.

Jaguar Health to Present at Lytham Partners Spring 2023 Investor Conference & Participate in Animal Health Panel

Jaguar Health, Inc. (NASDAQ:JAGX ) Q1 2023 Earnings Conference Call May 15, 2023 8:30 AM ET Company Participants Lisa Conte - President & Chief Executive Officer Sandra Swain - Professor of Medicine, Georgetown Kelly Shanahan - Patient Advocate Carol Lizak - Chief Financial Officer Ian Wendt - Chief Commercial Officer Conference Call Participants Operator Greetings and welcome to the Jaguar Health Investor Webcast. [Operator Instructions] Before I turn the call over to management, I'd like to remind you that management may make forward-looking statements relating to such matters as continued growth prospects for the company, uncertainties regarding market acceptance of products, the impact of competitive products and pricing, industry trends and product initiatives, including products in the development stage which may not achieve scientific objectives or meet stringent regulatory requirements.

Jaguar Health, Inc. (JAGX) Q1 2023 Earnings Call Transcript

Net revenue decreased in Q1 2023 versus Q1 2022 Net loss improved over the same period Jaguar has agreed, as described below, not to issue additional equity securities before October 22, 2023 - by which point the Company expects to have released top line data for the Phase 3 OnTarget trial Completed and core near-term milestones: Enrollment completed for Phase 3 OnTarget trial Submission of Investigational New Drug (IND) application planned for Q2 2023 to FDA for crofelemer for microvillus inclusion disease REMINDER: Jaguar to host investor webcast Monday, May 15th at 8:30 a.m. Eastern regarding first-quarter 2023 financials and company updates; Click here to register for webcast SAN FRANCISCO, CA / ACCESSWIRE / May 15, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today reported consolidated first-quarter 2023 financial results and provided Company updates.

Jaguar Health Reports First Quarter 2023 Financial Results

Click here to register for webcast Company plans to file its Earnings Report on May 15, 2023 on Form 10-Q for the quarter ended March 31, 2023 SAN FRANCISCO, CA / ACCESSWIRE / May 12, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today issued a reminder that the company will conduct an investor webcast on Monday, May 15, 2023 at 8:30 a.m. Eastern Daylight Time to review first-quarter 2023 financials and provide corporate updates.

REMINDER: Jaguar Health to Hold Investor Webcast Monday, May 15th at 8:30 AM EDT Regarding Q1 2023 Financials & Corporate Updates

Canalevia®-CA1 is the first and only treatment for CID in dogs to receive any type of approval from the FDA SAN FRANCISCO, CA / ACCESSWIRE / May 11, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") under its Jaguar Animal Health tradename for the veterinary market, today announced that Canalevia-CA1 (crofelemer delayed-release tablets), the company's U.S. Food and Drug Administration (FDA) conditionally approved prescription drug product for the treatment of chemotherapy-induced diarrhea (CID) in dogs, is now available on Chewy , a trusted destination for pet parents and partners everywhere. "We are thrilled to have added Chewy to the list of prominent pet retailers in the U.S. that offer Canalevia-CA1.

Canalevia-CA1, Jaguar Animal Health's FDA Conditionally Approved Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs, Now Available from Chewy

AI technology is expected to help make it faster and easier for Mytesi® patients to start and stay on the drug SAN FRANCISCO, CA / ACCESSWIRE / May 10, 2023 / Jaguar Health, Inc. (Nasdaq:JAGX) ("Jaguar" or the "Company") today announced that the Company has launched an artificial intelligence-powered web portal for U.S. healthcare professionals to support patient access to Mytesi (crofelemer), the Company's FDA-approved antidiarrheal prescription drug indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy. Access to the portal is available to U.S. healthcare professionals on the Mytesi Healthcare Professionals Site.

Jaguar Health Launches AI-powered Web Portal to Support Patient Access to Mytesi, the Company's FDA-approved Prescription Drug

Primary endpoint based on patient reported outcomes from study expected in October 2023 With the completion of the PIPE financing of unregistered shares and 6-month lock up term, Jaguar has agreed, as described below, not to issue additional equity securities before October 22, 2023 - by which point the Company expects to have released top line data for the OnTarget trial SAN FRANCISCO, CA / ACCESSWIRE / May 9, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that it has completed enrolling the target number of 256 patients in the Company's global, pivotal, Phase 3 OnTarget clinical trial of crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy with or without chemotherapy. "The Company's current cash position includes anticipated gross proceeds from a PIPE (private investment in public equity) transaction of approximately $1.86 million involving the issuance and sale of approximately 3,425,000 shares of unregistered Jaguar Common Stock and 6,850,000 warrants not exercisable until the later of January 1, 2024 and stockholder approval, that is expected to close on May 9, 2023, subject to customary closing conditions," said Lisa Conte, Jaguar's president and CEO.

Jaguar Completes Enrollment in Its Pivotal Phase 3 OnTarget Trial of Crofelemer for Prophylaxis of Cancer Therapy-Related Diarrhea

Click here to register for webcast Company plans to file its Earnings Report on May 15, 2023 on Form 10-Q for the quarter ended March 31, 2023 SAN FRANCISCO, CA / ACCESSWIRE / May 8, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Monday, May 15, 2023 at 8:30 a.m. Eastern Daylight Time to review first-quarter 2023 financials and provide corporate updates.

News for Jaguar Health Stock (JAGX)